Immix Biopharma, Inc. (IMMX)
NCM · Healthcare · Biotechnology
$8.45
+4.32%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$601.6M
Shares Outstanding
71.2M
Exchange
NCM
Currency
USD
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.7M | -7.7M | -10.9M | -10.8M |
| Net Income | -6.6M | -7.6M | -10.7M | -10.1M |
| Diluted EPS | $-0.22 | $-0.24 | $nan | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -8.2M | -16.1M | -22.7M | -30.0M |
| Net Income | -8.2M | -15.4M | -21.6M | -29.4M |
| Diluted EPS | $-0.59 | $-0.89 | $-0.76 | $nan |